Clinical Trials Logo

Glioblastoma or Gliosarcoma clinical trials

View clinical trials related to Glioblastoma or Gliosarcoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02197169 Completed - Clinical trials for Glioblastoma or Gliosarcoma

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

TARGET-I
Start date: September 11, 2014
Phase: Phase 1
Study type: Interventional

Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant primary brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase Ib study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified, conditionally replicative and oncolytic human-derived adenovirus. DNX-2401 is delivered directly into the tumor where it may establish an active infection by replicating in and killing tumor cells.